ArticleFrontiers in oncology2026
Predictors of false-negative serum thyroglobulin in persistent/recurrent Papillary Thyroid Carcinoma cervical lymph nodes.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Serum thyroglobulin (Tg) is the primary biomarker for monitoring disease persistence and recurrence in papillary thyroid carcinoma (PTC). However, some patients with structurally confirmed persistent/recurrent cervical lymph nodes (LNs) have low or undetectable Tg. This study aimed to identify predictors of false-negative unstimulated serum Tg (<0.2 ng/mL) and develop a predictive model. Patients and methods: This retrospective study enrolled 215 Papillary Thyroid Carcinoma patients who underwent total thyroidectomy and were confirmed to have persistent/recurrent cervical LNs. Multivariable logistic regression identified independent predictors associated with serum Tg <0.2 ng/mL. A nomogram was developed and validated by AUC, calibration curve, decision curve analysis (DCA). Results: Among the 215 patients (50 persistent, 165 recurrent), 48 (22.3%) had unstimulated serum Tg <0.2 ng/mL. Independent predictors of false-negative Tg (<0.2 ng/mL) were central LN compartment Conclusion: Central LN location, small LN size, and elevated Tg-Ab predict false-negative Tg in Papillary Thyroid Carcinoma patients with persistent/recurrent LNs. The nomogram identifies high-risk individuals (≥0.1), in whom serum Tg alone is unreliable and adjunct imaging and biopsy should be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.